Nithiodote Solution for Injection
Authorisation PA22874/003/001 · Hope Pharmaceuticals Ltd
- Licence holder
- Hope Pharmaceuticals Ltd (all products →)
- Active substances
- SODIUM NITRITE, Sodium thiosulfate
- Clinical trials
- 5 clinical trials →
- Dosage form
- Solution for injection
- Route of administration
- Intravenous use
- ATC codes
- V03AB, V03AB06, V03AB08
- First authorised
- 06/07/2018
- Prescription status
- Product subject to prescription which may not be renewed (A)
- Supply
- Supply through pharmacies only
- Legal basis
- Well-established use application (Article 10a of Directive No 2001/83/EC)
SODIUM NITRITE: supply and approvals
2 authorised products on the HPRA list contain SODIUM NITRITE. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.
- EU shortage (EMA)
- No entry in the EMA shortage catalogue (checked 21 Nov 2026)
- US shortage (FDA)
- No entry in the FDA drug shortage list (checked 21 Nov 2026)
- Germany (BfArM)
- No entry in the BfArM supply notices (checked 21 Nov 2026)
Registers: EU shortages · US shortages · German shortages · EMA approvals
Sodium thiosulfate: supply and approvals
3 authorised products on the HPRA list contain Sodium thiosulfate. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.
- EU shortage (EMA)
- No entry in the EMA shortage catalogue (checked 21 Nov 2026)
- US shortage (FDA)
- No entry in the FDA drug shortage list (checked 21 Nov 2026)
- Germany (BfArM)
- No entry in the BfArM supply notices (checked 21 Nov 2026)
Registers: EU shortages · US shortages · German shortages · EMA approvals
About this licence
National authorisation (PA). A product authorisation granted by the HPRA for the Irish market. It has been authorised for 8 years (since 6 July 2018). The HPRA list marks it as not marketed: it is licensed but the holder has not reported it as on sale.
Other medicines with SODIUM NITRITE in Ireland
1 other product on the HPRA list contains SODIUM NITRITE, from 1 licence holder; 0 of them are marked as marketed. Products with the same substance can differ in strength, form, other ingredients and what they are licensed for, so they are not automatically interchangeable.
| Medicine | Licence holder | Licence | Status |
|---|---|---|---|
| Sodium Nitrite Hope Pharmaceuticals 30 mg/mL Solution for Injection | Hope Pharmaceuticals Ltd | National authorisation (PA) | Not marketed |
Other medicines with Sodium thiosulfate in Ireland
2 other products on the HPRA list contain Sodium thiosulfate, from 2 licence holders; 0 of them are marked as marketed. Products with the same substance can differ in strength, form, other ingredients and what they are licensed for, so they are not automatically interchangeable.
| Medicine | Licence holder | Licence | Status |
|---|---|---|---|
| Pedmarqsi 80 mg/mL solution for infusion | Norgine B.V. | Centralised EU authorisation | Not stated |
| Sodium Thiosulfate Hope Pharmaceuticals 250 mg/mL Solution for Injection | Hope Pharmaceuticals Ltd | National authorisation (PA) | Not marketed |
Other substances in ATC group V03AB
The ATC system groups medicines by the part of the body they act on and their chemistry. On the HPRA list, 12 other active substances share the group V03AB with this product:
Hydroxocobalamin (2) · Naloxone hydrochloride dihydrate (2) · Flumazenil (1) · Sugammadex (1) · Fomepizole sulphate (1) · Methylthioninium chloride (1) · NALOXONE HYDROCHLORIDE (1) · Andexanet alfa (1) · Acetylcysteine (1) · Potassium iodide (1) · Idarucizumab (1) · Protamine sulphate (1)
Numbers in brackets are products on the HPRA list. Sharing an ATC group does not mean two medicines can replace each other.
The licence holder
Hope Pharmaceuticals Ltd holds 3 products on the HPRA list, with 2 different active substances; 0 of the products are marked as marketed.
This listing is regulatory information, not medical advice — consult the package leaflet, SPC, or a healthcare professional. For the authoritative record see the HPRA register.
How this page is built
The facts on this page are pulled directly from the HPRA's (Health Products Regulatory Authority) official open dataset — they are not written from memory, and nothing here is summarised or edited. Each field below names the dataset it came from, so you can check it yourself.
- HPRA Authorised Medicines List (open data) ↗ Licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status for this product
This page is built automatically: a daily sync job downloads HPRA's published XML export and copies the licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status directly into this page — no AI drafting and no per-product editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The HPRA data on this page was last retrieved on 22 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.